Organon & Co.

Organon & Co. is a global healthcare company focused on delivering impactful medicines and solutions for a healthier every day. The company offers a portfolio of over 70 products across women's health and general medicines, including biosimilars. Organon addresses health needs that uniquely, disproportionately, or differently affect women and expands access to essential treatments in over 140 countries and territories. Products are sold through various channels, including drug wholesalers and retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon operates six manufacturing facilities located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom. The company's operations include two main product portfolios: Women's Health: This portfolio consists of prescription products primarily in contraception and fertility. Key contraception brands include Nexplanon® (etonogestrel implant), sold as Implanon NXT™ in some countries outside the United States, and NuvaRing® (etonogestrel / ethinyl estradiol vaginal ring). Nexplanon is a long-acting reversible contraceptive. Key fertility brands include Follistim AQ® (follitropin beta injection), marketed in most countries outside the United States as Puregon™. The Jada® System, intended for abnormal postpartum uterine bleeding or hemorrhage, was divested to Laborie Medical Technologies Corporation in January 2026. General Medicines: This portfolio includes biosimilars and established brands. The current biosimilars portfolio covers immunology and oncology-related treatments. Oncology biosimilars, including Ontruzant® (trastuzumab-dttb), Aybintio™ (bevacizumab), Bildyos® (denosumab-nxxp), and Bilprevda® (denosumab-nxxp), have been launched in more than 20 countries.